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Abstract Axillary lymph node status is one of the most im-
portant prognostic variables for breast cancer (BC). To inves-
tigate and understand the clinical, histopathological and bio-
logical factors that affect prognosis in node-positive young
breast cancer patients, we compared the phenotype of 100
primary tumours with their corresponding loco-regional
lymph node (LN) metastases using conventional immunohis-
tochemistry (IHC) markers currently in use for molecular clas-
sification of breast cancer. By comparing the expression of
ER, PR, HER-2, Ki67, K8, K5/6 and vimentin, we found that
expression of HER-2, Ki67, K8 and vimentin is frequently
lost in lymph node metastases. Between the primary tumour
and corresponding lymph node metastases, expression of ker-
atins K8 and K5/6 significantly changed. Expression of K8 in
lymph node metastases, but not in primary tumours, segre-
gates patients in two sub-groups with different outcomes.
Survival of patients with K8-positive LNmetastases at 5 years
in comparison with patients with K8-negative LN metastases
was 75 vs 48 %, at 10 years 62 vs 22 % and at 20 years 53 vs
14% (p<0.001). K8 immunostaining of tissue from the lymph
node metastasis allows defining a sub-group of lymph node-
positive BC patients with a highly unfavourable outcome, for
whom therapeutic options might have to be reconsidered.
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Introduction
Axillary lymph node status is one of the most relevant prog-
nostic factors in primary breast cancer (BC). Patients with
metastases to axillary lymph nodes (LN) are at higher risk of
recurrence [1, 2]. It has been estimated that almost 50 % of
patients with positive lymph node involvement will develop
distant metastases within 5 years, while women without
lymph node involvement have a 30 % risk [1]. Many clinical
and pathological parameters such as tumour size, tumour
grade, age at diagnosis [2–4], lympho-vascular invasion [5],
hormone receptor status and HER2 amplification [6, 7] are
generally considered as predictors of recurrence. Although
these clinical and biological factors are significantly associat-
ed with the presence of lymph node involvement, they fail to
predict the development of later recurrences [1]. Today, we are
unable to distinguish among lymph node-positive BC patients
those with high and low risk of recurrence. Comparing path-
ological and molecular characteristics between primary tu-
mours and corresponding metastatic sites might help not only
to understand heterogeneity and biology of the metastatic pro-
cess but also to predict patient outcome [8], especially in those
young patients who already present with axillary node metas-
tases at initial diagnosis.
Molecular classification of BC is associated with clinical
behaviour and outcome [9, 10]. BC can be molecularly clas-
sified according to expression of oestrogen receptor (ER),
Danae Pracella contributed equally to this work.
Electronic supplementary material The online version of this article
(doi:10.1007/s00428-015-1748-1) contains supplementary material,
which is available to authorized users.
S. Bonin :D. Pracella : R. Barbazza :G. Stanta (*)
Department of Medical Sciences, University of Trieste, Cattinara
Hospital, Strada di Fiume 447, Trieste, Italy
e-mail: stanta@icgeb.org
S. Sulfaro
Department of Laboratory Medicine, S.C. Pathology, Santa Maria
degli Angeli Hospital, 33170 Pordenone, Italy
Virchows Arch
DOI 10.1007/s00428-015-1748-1
progesterone receptor (PR) and HER2, and the Ki67
expression-based index of proliferation [11] as well as type
of expressed keratin (K) [12–14]. Ks are the largest family of
intermediate filaments [15]. As part of their diversity in num-
ber, structure and tissue-specific expression, Ks serve as im-
portant immunohistochemical markers, also because during
tumour progression, the pattern of Ks expression in primary
tumour tissue is often maintained in metastases [16]. The ep-
ithelium of breast duct and lobules contains luminal and
basal/myoepithelial cells [17]. Luminal cells express low
molecular weight Ks, such as K7, K8, K18 and K19, while
basal/myoepithelial cells [18] express high molecular weight
Ks, such as K5 and K14 [17].
A wide range of biomarkers has been studied in primary
BC and matched LN metastatic tissue, but to date, biomarker
is not used for prognostic purposes [19–25]. Our aim in this
study was to compare the expression of biomarkers in daily
use for BC classification (ER, PR, HER2, Ki67) and BC phe-
notypic differentiation (K8 for luminal cells, K5/6 for basal/
myoepithelial and vimentin as EMTmarker) between primary
and matched nodal tumour tissue and to investigate the rela-
tionships between primary tumour and metastatic LN as well
as potential prognostic relevance in axillary LN metastases.
Material and methods
Patients
One hundred lymph node-positive (LN+) patients with locally
advanced BC at diagnosis were enrolled in this retrospective
study. Inclusion criteria were women with stages II–III inva-
sive BC, age at diagnosis 55 years or younger, long follow-up
if still alive and absence of second primary BC or other ma-
lignancies. All women were resident in North-Eastern Italy
and received a diagnosis of primary BC at least 20 years be-
fore the censoring date of the study (31 December 2013) as
reported previously [14]. According to those criteria, 154
women were selected, 54 of whom were excluded due to the
impossibility to perform all IHC analyses, because of the min-
imal amount of metastatic node tissue. Formalin-fixed and
paraffin-embedded (FFPE) tissues from the initial surgical in-
tervention were used. Clinical information on follow-up was
obtained from medical records.
H&E slides of primary tumours and metastatic lymph
nodes were revised in double-blind fashion by two patholo-
gists (R.B., G.S.). Histologic classification and tumour grad-
ing were done according to the World Health Organization
(WHO 2003) [26] and Elston and Ellis grading system [27]
respectively. The cohort of patients was followed through the
general population-based Friuli Venezia Giulia Cancer
Registry from the date of BC diagnosis to death or until 31
December 2013, whichever came first. The Ethics Committee
of the University of Trieste had given its approval for the
study. The patients enrolled in the present study had also been
part of a previous study [14].
Tissue microarrays
Representative areas of both primary tumour and correspond-
ing metastatic regional nodes were selected by two patholo-
gists (G.S. and R.B.) for TMA construction. Tissue cores were
of 1.0 mm in diameter taken at the border of the primary
tumour in the donor paraffin block and placed into a recipient
paraffin block using a tissue-arrayer (Galileo TMA CK3500;
Integrated Systems Engineering, Milano, Italy), as previously
described [28]. Multiple samples were taken to represent het-
erogeneous histological areas. Of each TMA block, 4-μm
thick sections were cut, mounted on Superfrost® Plus
(Thermo Scientific) microscope slides and heated at 37 °C
overnight for IHC analysis.
Immunohistochemical staining
IHC staining was performed following standard procedures
[29], according to the manufacturer’s instructions for each
MAb as reported previously [14]. Immunostaining was per-
formed with the Vectastain Universal Elite ABC kit (Vector
Laboratories, Burlingame, CA, USA) for ER, PR, K8, K5/6
and vimentin. Prediluted antibodies for ER (CONFIRM™
anti-Estrogen Receptor clone SP1; Ventana Medical System,
Tucson, AZ), PR (CONFIRM™ anti-Progesterone Receptor
clone 1E2; Ventana Medical System, Tucson, AZ), vimentin
(CONFIRM™ anti-Vimentin clone V9; Ventana Medical
System, Tucson, AZ) and 1:100 dilution for K5/6 (clone
D5&16B4; Aczon Biotech, Monte San Pietro, Bologna,
Italy) were applied after antigen retrieval in 0.1 M pH 8
Tris-Borate, 1 mM EDTA at high temperature. Anti-K8 anti-
body (cloneM20; Abcam, Cambridge, UK) was used at 1:250
dilution after antigen retrieval in 10 mM citrate buffer pH
6 at high temperature in a water bath. For visualisation,
DAB Substrate kit for Peroxidase (Vector Laboratories,
Burlingame, CA, USA) was used. Immunostaining for Ki67
(clone MIB-1; DakoDenmark A/S, Glostrup, Denmark),
1:200 dilution, and HER-2 (clone CB11; Thermo Scientific,
Astmoor Runcorn, Cheshire, UK), 1:300 dilution, was per-
formed in Lab Vision Autostainer 480S (Thermo Scientific)
with the UltraVision LP LargeVolumeDetection SystemHRP
Polymer (Lab Vision Corporation, Thermo Scientific) accord-
ing to the manufacturer’s recommended protocol. Briefly, af-
ter deparaffinisation and rehydration, tissue sections were
washed twice in 0.05 M TBS + Tween 20 (Bio-Optica).
Tissue slides were treated with high pH antigen retrieval for
20 min in heated water bath and washed four times. To reduce
non-specific background staining, endogenous peroxidase
was blocked with hydrogen peroxide for 10 min. Primary
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antibodies were applied and incubated according to the man-
ufacturer’s instructions. Subsequently, the sections were incu-
bated with primary antibody Enhancer (LabVision, Thermo
Scientific) for 20 min at room temperature. After washing,
HRP Polymer was applied for 30 min at room temperature.
For visualisation, chromogen 3,3′-diaminobenzidine (DAB)
(LabVision, Thermo Scientific) was used. Positive and nega-
tive control slides were used in each IHC assay.
Evaluation of immunohistochemistry
Immunostaining was quantitatively evaluated by two different
observers in a blinded fashion (DP, RB), using light micros-
copy and counting positive cells across three high power fields
(HPF at × 40 magnification). Tumours were considered pos-
itive for ER and PR if more than 10 % of tumour nuclei were
stained [30, 31, 21], because this was the cut-off used for
giving hormone therapy at the time of diagnosis. HER-2 ex-
pression was scored according to ASCO guidelines [32].
HER-2 gene amplification in the case of equivocal staining
(2+) was assessed by SISH assays using the ultraView SISH
DNP Detection Kit (Ventana) in Benchmark XT automated
slide strainer instrument, as previously described [33].
Primary tumours and lymph node metastases positive in more
than 10% of cells were defined as positive for K8 and K5/6 as
reported previously for keratins in BC [34, 35]. Nevertheless,
also a 1 % cut-off was recorded and independently estimated
for K8 (data not shown) with minimal variation in the results
as shown in Supplementary Fig. 2. Any positive staining in
tumour cells for vimentin was considered as positive expres-
sion [36]. Tumours were stratified into two groups according
to their proliferative activity: Ki67 threshold of 14%was used
to discriminate low proliferation index (<14 %) and high pro-
liferation index (≥14%) [37, 11]. Tumours were classified into
four main molecular classes according to ER, PR, HER-2,
Ki67, K8 and K5/6 staining profile [37, 38, 11, 39]. Cases
ER-positive and/or PR-positive, HER-2-negative, low Ki67
and K8-positive were classified as Luminal A, cases either
(i) ER-positive and/or PR-positive, HER-2-negative, high
Ki67 and K8-positive, or (ii) ER-positive and/or PR-positive,
and HER-2-positive were classified as Luminal B, tumours
ER-negative, PR-negative and HER-2-positive were defined
HER-2+ type, and cases ER-negative, PR-negative, HER-2-
negative and K5/6-positive were classified as triple negative
(TN), which is considered a surrogate for basal-like [40]. If
primary tumour or lymph node metastatic tissue staining pat-
tern did not meet one of the above-mentioned panel criteria,
the case was defined as ‘unclassified’.
Statistical analysis
Staining for each marker was dichotomised into negative and
positive expression, according to the previously described
parameters. Marker expression was compared between prima-
ry tumour and lymph node metastasis using the Wilcoxon
matched-pairs signed-ranks test. Associations between
clinical-pathological factors and categories of markers were
tested for significance using the chi-square test (or Fisher’s
exact test depending on sample size) for categorical variables.
Overall survival (OS), defined as the time lapse between the
date of diagnosis and the date of BC-specific death or the end
of follow-up (FU), was the end point evaluated in this study.
The log-rank test and Kaplan-Meyer curves were used to as-
sess dependence of patient survival on single variables. To
estimate the joint effects of the analysed covariates on patient
survival and confirm the results of the log-rank test, data were
analysed by fitting Cox proportional hazard regression model.
Cox analysis included pathological variables (histologic type
of tumour, tumour grade, tumour size, number of positive
lymph nodes and age at diagnosis), K8 expression status in
lymph node metastases and molecular subtype of BC. As
post-estimation for the proportional hazards assumption the
Grambsch and Therneau test for Schoenfeld residuals was
run. All p values are two-sided with values <0.05 regarded
as statistically significant. The p values between 0.05 and 0.07
were considered as ‘borderline’. Statistical analyses were
performed with the Stata/SE 12 package (Stata, College
Station, TX).
Results
Patients
Mean age of patients at diagnosis was 47.6 years (range 28–
55). During the period of observation, nine patients were lost
at follow-up because of emigration. All details are reported in
Table 1. As expected for histologic grade, most cases were of
grade 2 (42 %) and grade 3 (56 %). The number of metastatic
lymph nodes was up to three for 49 women and more than
three for 51.
Patients underwent radical mastectomy and breast conser-
vation surgery accompanied by axillary dissection. All pa-
tients submitted to conserving surgery (10) were treated with
radiotherapy. In detail, in patients with three or fewer lymph
nodes involved, only the breast was irradiated; in patients with
more than three metastatic lymph nodes with capsule inva-
sion, both breast and axilla were irradiated. Patients were treat-
ed with adjuvant chemotherapy with cyclophosphamide,
methotrexate and fluorouracil (CMF), or epirubicin, cyclo-
phosphamide and fluorouracil (EC/ECF) regimens according
to standard protocols. ER-positive patients were submitted to
hormone therapy with tamoxifen. No specific treatment with
trastuzumab was performed in HER2+ patients, because it
was not available at the time of diagnosis.
Virchows Arch
The mean period of follow-up was 11 years (range 0–
28 years). In this period, 67 patients developed recurrences,
while 24 did not.
Comparison of markers expression between primary tumour
and correspondent axillary LN metastasis
The expression of five out of seven markers (HER-2, Ki67,
K8, K5/6, vimentin) was significantly different between pri-
mary tumour and corresponding loco-regional metastases as
reported in Table 2 and in Supplementary Data. Most markers
were more often positive in the primary tumour than in the
corresponding lymph node metastases, but K5/6 was more
often positive in lymph node metastases (46 %) than in the
corresponding primary tumour (19 %) (p<0.001).
Vimentin was concordant in primary and metastatic tumour
tissues in 53 cases, positive only in primary BC in 30 cases
and only in LN in 16 cases. Vimentin expression in LN me-
tastases was related to early BC death (<5 years) (p=0.02).
Relationship of markers with clinical and pathological
features
The relationship between marker expression and clinical path-
ological features was evaluated for both primary tumours and
corresponding metastatic nodes. Only significant associations
are reported here.
ER- and PR-negative primary tumours were of higher his-
tological tumour grade (p=0.004 for ER, p=0.06 for PR).
This result was also confirmed for lymph node metastases
(p=0.002 and p=0.05 for ER and PR, respectively). Less
differentiated primary tumours were mainly HER-2-positive
and Ki67 high (p=0.04 and p=0.02 respectively). HER-2-
positive metastases were also more often less differentiated
(p=0.001). Patients with higher tumour grade had frequently
K5/6-positive lymph node metastases (p=0.009), but not pri-
mary tumours (p=0.2). Absence of K8 expression in lymph
node metastases was significantly associated with the devel-
opment of recurrence (p=0.04).
Molecular classification
Based on IHC results, BC primary tumours were classified as
follows: 28 luminal A, 45 luminal B, 14 HER-2+ and 13 TN
subtypes. There were no significant differences in age at di-
agnosis betweenmolecular subtypes (p=0.2), even for women
of less than 40 years (p=0.6). Molecular subtypes were con-
cordant between primary BC and LN in 54 patients (54 %). In
non-concordant cases (46 cases), about 60 % (28 cases) LN
metastases were of a less aggressive subtype, as shown in
Table 3. IHC staining for each marker in primary tumours
and corresponding lymph node metastases is reported in detail
in Supplementary File 1 and in Supplementary Results.
Table 2 Immunohistochemistry-positive results for BC primary
tumours and corresponding loco regional metastasis (N=100 cases)
Markers Primary tumour Node metastases p value
ER 73 % 77 % 0.1
PR 61 % 70 % 0.3
HER-2 33 % 24 % 0.04
Ki67≥14 % 66 % 39 % 0.0003
K8 89 % 59 % <0.001
K5/6 19 % 46 % <0.001
Vimentin 44 % 30 % 0.04
Table 3 Schematic representation of molecular classification in
primary tumour and metastatic lymph nodes
Primary tumour→
Metastatic LN ↓
Luminal A
(28)
Luminal B
(45)
TN/basal
(13)
Her2+ non-
luminal (14)
Luminal A 18 21 0 0
Luminal B 8 24 2 4
TN/Basal 1 0 8b 1
Her2+ non-luminal 0 0 1 8
Unclassified 1a 0 2c 1d
In the first row, classification refers to primary BC; in brackets, the num-
ber of cases is shown. In the columns, the number of cases related to the
specific molecular subtype detected at the LN level is reported
a The case was positive for PR only
b Six LN were classified as basal and two as TN
cOne cases was PR+, ER−, HER-2+, K5/6+ and K8− and the other one
was PR+, ER−, HER-2−, K5/6+ and K8−
d This case was unclassified because it is not evaluable
Table 1 Main
pathological features Variable Number of cases
Histologic type
Ductal 88
Lobular 10
Mucinous 2
Histologic grade
1 2
2 42
3 56
Tumour size (cm)
≤2 42
2–5 49
≥5 7
Missing 2
Stage
II 43
III 57
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Survival analysis
At the end of follow-up, 21 women were alive, 9 died of any
cause different from BC and 61 patients died from breast
carcinoma. Nine patients were lost to follow-up.
K8 expression in loco-regional metastasis was signif-
icantly associated with BC-specific survival in the entire
cohort of patients. K8 expression in lymph node metas-
tasis was associated with longer survival (p<0.001), as
shown in Fig. 1. Conversely, expression of K8 in the pri-
mary tumour did not significantly affect BC-specific survival
(p=0.5), (Supplementary Fig. 1). Of note, 33 patients lost
expression of K8 in loco-regional metastases, while the pri-
mary tumour was positive, and 27 of those died of BC
(p<0.001) (Fig. 2). Survival analysis according to K8
expression in LN metastases stratified per molecular sub-
type showed that K8-positive LN metastasis is significantly
associated with BC-specific survival only in patients with lu-
minal subtype (p=0.03 for luminal A and p=0.0005 for lumi-
nal B, p<0.001 for luminal A and B together), but not in HER-
2+ and TN subtypes (p=0.2 and p=0.9, respectively) as
shown in Fig. 2. The hazard ratio for BC-specific death in
patients with K8-negative loco-regional metastasis overall
was 4.4 times as high as in patients with K8-positive LN
metastases (p=0.001), and in patients with luminal primary
BC, this was even 5.2 (95 % confidence interval 1.52–20.0;
p=0.003). Survival for patients with K8-positive LN metasta-
ses compared to those negative was 75 vs 48 % at 5 years, 62
vs 22 % at 10 years and 53 vs 14 % at 20 years. A represen-
tative image of K8 staining in primary BC and synchronous
lymph node metastasis is shown in Fig. 3. Loss of expression
in lymph node metastases of keratin 18, functionally related to
K8, was also related to worse prognosis and cancer-specific
death (data not shown).
Cox regression analysis confirmed the result on K8 expres-
sion obtained by Log-rank test. Multivariate survival analysis
showed a significantly worse prognosis only for the number of
positive lymph nodes (more than three positive) (p=0.03)
with a protective effect for LN metastases expressing K8
(p<0.001), as shown in Table 4. Tumour grade, size and his-
tological type did not influence patient survival because of the
population selected for our study. Post-estimation test for Cox
regression revealed that the proportional-hazard assumption
has not been violated. No significant differences in overall
survival were detected for the other biomarkers.
Discussion
Axillary lymph node status (LN) and ER status are the most
important prognostic variables for breast cancer patients. In
this study, we analysed 100 BC patients aged 55 years or less
with involvement of loco-regional axillary lymph nodes at
initial diagnosis.
Concordance of BC subtypes based on molecular classifi-
cation was found in most cases (54 %), in agreement with
others [21]. Incongruity between primary BC and synchro-
nous metastatic LN cannot be ascribed to pre-analytical con-
ditions because both specimens were collected during the
same surgical intervention, prior to any therapy and processed
simultaneously with the same workflow andmethodology. All
specimens were conventionally fixed in 10% neutral-buffered
formalin for a maximum fixation time of 48 h including pre-
fixation time in formalin.
In non-concordant cases (46 %), the molecular subtype of
the LN metastasis was mostly less aggressive, highlighting
heterogeneity in tumour progression. In very few cases
(as shown in supplementary results), acquisition of ER
or PR in LN metastases might be due to the use of a 10 %
cut-off at the time of diagnosis. Discordance in ER, PR and
HER2 status between primary tumour and metastatic lesions
was reported before, including acquisition of the biomarker in
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Fig. 1 Kaplan-Meyer overall survival curves according to K8 expression
in axillary metastatic LN
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Fig. 2 Kaplan-Meyer overall survival curves according to K8 in axillary
metastatic LN in patients with primary luminal breast cancers
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LN metastases [41, 42] as a consequence of tumour heteroge-
neity. Synchronous axillary lymph node metastases, even
though local, may contain potentially distant metastatic breast
cancer cells. Hence, determination of hormone receptor and
HER2 status in synchronous axillary nodal metastasis, along
with that of the primary tumour, may help to guide therapy
and to evaluate the risk of recurrence of lymph nodemetastatic
primary invasive breast cancer [42].
Other authors reported a lower frequency of subtype dis-
cordance mostly with a shift towards a more aggressive sub-
type [22], especially in luminal A patients. Variation between
primary tumour and metastasis might be explained by a vari-
ety of factors ranging from clonal selection during the meta-
static process [43] to phenotypic plasticity related to a new
microenvironment in lymphatic tissue [44]. Concordant ex-
pression of IHC markers in primary and node metastatic sites
might reflect metastatic cells utilizing gene sets similar to
those in the primary tumour. Discordant expression might
reflect metastatic cells using a distinctly different set of genes
[45]. Breast cancer tissue contains molecularly heterogeneous
cell populations [46]. Consequently, it is not surprising that
the IHC profile of the primary tumour and its lymph node
metastases is not always identical. Metastatic tumour deposits
are not exact morphological or a molecular replicas of the
primary neoplasms from which they arose; as a consequence,
metastatic tumours at different sites may display widely dis-
parate features [47].
In our study, the expression of five out of seven markers
was significantly different (HER-2, Ki67, K8, K5/6,
vimentin). Ki67, HER2 and vimentin were less expressed in
node metastases than in primary tumours, suggesting less ag-
gressive metastatic clones. Loss of HER2 amplification in
synchronous lymph node metastases with prognostic implica-
tions has been reported previously [41]. The Ki67 labelling
index in LN metastases was significantly lower than in
matched primary tumours (data not shown), in agreement with
Fig. 3 Immunohistochemical
stain for K8 in primary breast
cancers (a, c, e) and paired
synchronous metastatic lymph
nodes (b, d, f). Magnification ×
20. a, b and c, d refer to K8
positivity in both primary BCs
and metastatic LN, while e–f refer
to loss of K8 at the LN level
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Cabibi et al. [20]. Other authors reported significant
increase in Ki67 labelling index in metastases as com-
pared with primary tumours [48]. However, case study
selection and cut-off criteria could account for these
discrepancies.
K8 was less frequently expressed in metastases, while only
of K5/6, the expression rate in loco-regional metastatic lymph
nodes increased, but without any impact on survival. We
hypothesise that as a result of clonal selection, tumour cells
with basal/myoepithelial characteristics more easily colonise
lymph nodes. K5/6 expression in primary BC has been
associated with a higher number of metastatic lymph
nodes [49]. K5/6-positive BC has a poor prognosis, also
in TN patients [49], but to our knowledge, there are no
reports on K8 and/or K5/6 expression in LN metastases
of BC. A single study [50] reports decreased expression
only of K5 in metastatic LN.
Vimentin, a marker of mesenchymal phenotype, is more
frequently expressed in lymph node metastases than in
matched primary BC [23]. We found vimentin expression
more often in primary BC than in corresponding LN metasta-
ses. This disagreement might be ascribed to differences in
scoring, as in the earlier study, low expressing and negative
cases were put together in a single group [23]. Biomarker
expression in loco-regional lymph nodes might not have the
same prognostic value as their expression in the primary tu-
mour. Our findings are in agreement with those reported by
Cummings et al. [47] who proposed that treatment decisions
should not be based only on morphological features of the
primary tumour, as key biological attributes of metastases
may significantly affect disease outcome [47].
Although in our cohort, K8 expression in primary tumours
did not have any impact on prognosis (Supplementary Fig. 1),
K8 expression in lymph node metastasis was predictive for
better survival. Conversely, most patients (27 out of 33) with a
primary tumour expressing K8 but with negative loco-
regional LN metastases died of BC. K8 expression status af-
fected survival only in luminal BC patients in our cohort. This
cannot be explained as an effect of therapy, because as a rule,
patients with luminal BC derive less benefit from chemother-
apy [51]. All our ER+ patients received tamoxifen and adju-
vant chemotherapy, and those with loss of K8 expression in
lymph node metastases died of BC within 10 years. This find-
ing might have implications for treatment of this sub-group of
BC patients, for whom conventional chemotherapy does not
prevent late recurrence [52].
IHC staining for K8 LN metastases allows to identify a
sub-group of lymphnode-positive luminal BC patients with
highly unfavourable outcome: The risk of BC-specific death
among patients with K8 negative loco-regional metastases
was 4.6 times as high as in patients with K8-positive LN
metastases. Log-rank and multivariate analysis showed that
only the number of positive lymph nodes and K8 expression
in LN metastases remains as independent variables affecting
survival (Table 3). This was corroborated by IHC staining of
K18, functionally related to K8, of which loss of expression in
lymph node metastases was associated with poor prognosis
and cancer-specific death (data not shown). Loss of K8 ex-
pression in LN metastases might identify less differentiated
and more aggressive tumour cells. While responsible
mechanisms are unclear, a possibility is K8 function as
plasminogen receptor on the cell surface of BC cells,
which has been associated with increased invasiveness
in vitro and in vivo [53]. Other experiments showed re-
duced expression of K8 along progression of human breast
cancer into an invasive phenotype [54]. Furthermore, Iyer
et al. reported that K8 expression is correlation with a less
invasive phenotype, while loss of K8 characterises highly in-
vasive dedifferentiated cancers [18].
A limitation of our study is that it was performed on TMAs,
which might not reflect tumour heterogeneity in full. To over-
come this limitation, multiple areas were selected and includ-
ed in the TMA. An additional limitation might be our case
selection criteria: patient age, stage of disease and LN-positive
status. Our conclusions indeed apply only to LN-positive (ex-
cluding micro- or very small LN metastases) stage II or III
young (55 years or less at diagnosis) breast cancer patients.
Our data strongly support the hypothesis that bio-
markers can have a different biological meaning in me-
tastases: Markers useful for prognosis in primary tu-
mours such as Ki67 might be less or not at all infor-
mative in lymph node metastases.
Table 4 Cox multivariate regression analysis for hazard ratio in breast
cancer survival
Variable HR 95 % confidence
interval
p value
Histologic type
Lobular vs ductal 1.34 0.58–3.1 0.5
Histological gradea 1.07 0.64–1.78 0.8
Tumour sizeb 0.89 0.56–1.43 0.6
Number of positive nodesc 1.83 1.04–3.23 0.04
Age at diagnosisd 1.02 0.98–1.08 0.2
K8 in metastatic LNe 0.40 0.23–0.72 0.002
Molecular subtypes
Luminal B vs luminal A 1.04 0.59–1.98 0.9
HER2+ vs luminal A 2.55 1.02–6.32 0.04
TN vs luminal A 1.87 0.74–4.75 0.2
a Grade of the tumour was a continuous variable
b Tumour size was included as categorical variable as follows: 1 and
≤2 cm, 2 and >2 cm, or ≤5 cm, and 3 and >5 cm
cNumber of positive lymph nodes: ≤3 or >3
dAge at diagnosis was a continuous variable
e Dichotomized in negative or positive
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Conclusions
Loss or absence of expression of keratin 8 in lymph node
metastases appears to define a sub-group of young (less than
55 years) stage II or III patients with a luminal type of breast
cancer, with a more aggressive clinical course. Biomarker
expression patterns in primary tumours might not have the
same meaning as those in metastatic lesions, which empha-
sises the need to include metastatic tissue in IHC marker stud-
ies. Larger validation studies are needed to confirm our find-
ings, but if confirmed, K8 expression might be used for prog-
nosis and therapy in lymph node-positive luminal breast can-
cer patients.
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